MedTrace Logo

Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

NCT02169440 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-12-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.

Conditions

  • Parkinson's Disease (PD)

Interventions

DRUG

BIA 9-1067

BIA 9-1067 25 mg

DRUG

Warfarin

Warfarin 25 mg

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • Portugal

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02169440 on ClinicalTrials.gov